clarification on analysis for different doses [Design Issues]

posted by Pandu – India, 2008-02-25 12:52 (6694 d 18:07 ago) – Posting: # 1629
Views: 3,419

Hello,

I want clarification on analysis for the following study:

We are doing pilot Bio-study on particular product. Here Reference product (15 mg) strength is double the Test product (7.5 mg). Now in clinical portion first we given both test (7.5 mg) and reference (15 mg) products according to randomization. After 8 hours again one Test product (7.5 mg) was given. Now total strengths are equal? In analysis we got 2 peaks for Test product (i.e. 1st dose and after 2nd dose). Here my doubt is that which Cmax we can take for Test product? Remaining PK parameters also how to I calculate.

Please give the reply as early as possible

Regards,
Pandu

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
117 visitors (0 registered, 117 guests [including 10 identified bots]).
Forum time: 07:59 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5